Bayer and Amgen clocked another failed indication-expansion effort for the cancer drug Nexavar. The companies announced Friday the drug did not hit its Phase-III primary target of improving progression-free survival among patients receiving both Nexavar and chemotherapy. The RESILIENCE study focused on patients with HER2-negative breast cancer who are resistant to, or failed on, taxane therapy or who have failed on anthracycline or for whom anthracycline is not indicated.
The companies also had a setback in March when they announced Nexavar failed to hit the Phase-III target of recurrence-free survival among liver-cancer patients when used as an adjuvant therapy.
